Patients in the experimental group of ND0612 demonstrated favourable efficacy over IR-LD/CD. Data showed a statistically significant increase (p<0.0001) of 1.72 hours in “ON” time without troublesome dyskinesia. The trial also demonstrated positive and clinically meaningful results for the first four secondary endpoints, including a reduction of “OFF” time (p<0.0001).
Mitsubishi Tanabe Pharma Corporation has ... - Cure Parkinson's
Mitsubishi Tanabe Pharma Corporation has announced that a Phase III trial of its Parkinson’s disease candidate has met its primary endpoint.
Written by
Farooqji
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
I know several posts have been made regarding the exanatide trials, but I just stumbled across this...
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
https://www.prnewswire.com/news-releases/annovis-bio-announces-completion-of-phase-iii-parkinsons-di
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
As of 24 Feb 2024:
- Recruitment continues and is reaching the halfway point (59 of 120);
- 25...
Isn't this the most dramatic trial so far?
I haven't seen a reference to it on this site. Does anyone know if this has been discussed?
When I...
Benfotiamine In The Mix For PD Again?
The following new animal study (December 2023) suggests that the fat soluble form of vitamin B1,...